The trajectory of Sildenafil presents a complex case for stakeholders in the drug sector. While initially a phenomenal success, generating huge profits, the exclusivity end and the subsequent arrival of generic versions have significantly affected earnings. This raises questions about the ongoing viability of related therapeutic developments and su